Ibandronate: its pharmacology and clinical efficacy in the management of tumor-induced hypercalcemia and metastatic bone disease

References

• Roodman GD. Mechanisms of bone metastasis. N Engl. J Med. 350, 1655–1664 (2004).
   PubMed Web of Science ®Google Scholar
• •Exellent review article on the development of bone metastases.
   Google Scholar
• Roodman GD. Biology of osteoclast activation in cancer. JOncol. 19, 3562–3571 (2001).
   Google Scholar
• Keller ET. The role of osteoclastic activity in prostate cancer skeletal metastases. Drugs Today38, 91–102 (2002).
   PubMedGoogle Scholar
• Widler L, Jaeggi KA, Glatt M et al. Highly potent geminal bisphosphonates. From pamidronate disodium (Aredia) to zoledronic acid (Zometa). J Med. Chern. 45,3721–3738 (2002).
   Google Scholar
• Frith JC, Rogers MJ. Antagonistic effects of different classes of bisphosphonates in osteoclasts and macrophages in vitro. J Bone Miner. Res. 18, 204–212 (2003).
   PubMed Web of Science ®Google Scholar
• Green JR. Antitumor effects of bisphosphonates. Cancer 97\(Suppl. 3), 840–847 (2003).
   Google Scholar
• Van Beek E, Pieterman E, Cohen L et al. Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates. Biochern. Biophys. Res. Corn. 264, 108–111 (1999).
   PubMed Web of Science ®Google Scholar
• Senaratne SG, Pirianov G, Mansi JL et al. Bisphosphonates induce apoptosis in human breast cancer cells. Br. J Cancer 82, 1459–1568 (2000).
   PubMed Web of Science ®Google Scholar
• Lee MV, Fong EM, Singer FR et al. Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Res. 61,2602–2608 (2001).
   PubMed Web of Science ®Google Scholar
• Boissier S, Magnetto S, Frappart L et al. Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res. 57,3890–3894 (1997).
   PubMed Web of Science ®Google Scholar
• Teronen O, Heikkild P, Konttinen YT et al. MMP inhibition and downregulation by bisphosphonates. Ann. NY Acad. Sci. 878, 453–465 (1999).
   PubMed Web of Science ®Google Scholar
• Sahni M, Guenther HL, Fleisch H et al. Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. J Clin. Invest. 91, 2004–2011 (1993).
   PubMed Web of Science ®Google Scholar
• Hiraga T, Williams PJ, Mundy GR et al. The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases. Cancer Res. 61,4418–4424 (2001).
   PubMed Web of Science ®Google Scholar
• Corey E, Quinn JE, Brown LG et al. Examination of the effects of zoledronic acid on prostate cancer. J Bone Miner. Res. 16\(Suppl. 1), S192 (2001).
   Google Scholar
• Bauss F, Russel RGG. Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing. Osteoporosis Int. 15(6), 423–433 (2004).
   Google Scholar
• Bauss F, Endele R, Besenfelder E et al. Ibandronate: serum kinetics, tissue distribution and binding to bone following intravenous bolus injection. Caldf. Tissue Int. 70,289–290 (2002).
   Google Scholar
• Monier-Faugere MC, Geng Z, Paschalis EP et al. Intermittent and continuous administration of the bisphosphonate ibandronate in ovariohysterectomized beagle dogs: effects on bone morphometry and mineral properties. J Bone Miner. Res. 14,1768–1778 (1999).
   PubMed Web of Science ®Google Scholar
• Bauss F, Lalla S, Endele R et al. The effects of treatment with ibandronate on bone mass, architecture, biomechanical properties and bone concentration of ibandronate in ovariectomized aged rats. Rheurnatol. 29,2200–2208 (2002).
   PubMed Web of Science ®Google Scholar
• Hoffmann-LaRoche. Ibandronate in tumour-induced hypercalcemia. Product Monograph, Data on File (1999).
   Google Scholar
• Ravn P, Neugebauer G, Christiansen C. Association between pharmacokinetics of oral ibandronate and clinical response in bone mass and bone turnover in women with postmenopausal osteoporosis. Bone 30,320–324 (2002).
   Google Scholar
• Bergner R, Dill K, Boerner D et al. Elimination of intravenously administered ibandronate in patients on hemodialysis: a monocentre open study. Nephrol. Dial. Tiansplant 17,1281–1285 (2002).
   PubMed Web of Science ®Google Scholar
• Smith SY, Recker RR, Hannan M et al. Intermittent intravenous administration of the bisphosphonate ibandronate prevents bone loss and maintains bone strength and quality in ovariectomized cynomologus monkeys. Bone 32,45–55 (2003).
   PubMed Web of Science ®Google Scholar
• Glueer CC, Scholz-Ahrenz KE, Timm W et al. The minipig is a good model for glucocorticoid-induced bone loss and shows efficacy of ibandronate for this disorder. J Bone Miner. Res. 17\(Suppl. 1), S371 (2002).
   Google Scholar
• Geng Z, Monier-Faugere MC, Bauss F et al. Short-term administration of the bisphosphonate ibandronate increases bone volume and prevents hyperparathyroid bone changes in mild experimental renal failure. Clin. Nephrol. 54,45–53 (2000).
   PubMedGoogle Scholar
• Pecherstorfer M, Ludwig H, Schlosser K et al. Administration of the bisphosphonate ibandronate (BM 21.0955) by intravenous bolus injection. J Bone Miner. Res. 11, 587–593 (1996).
   Google Scholar
• Coleman RE, Purohit OP, Black C et al. Double-blind, randomised, placebo-controlled dose finding study of oral ibandronate in patients with metastatic bone disease. Ann. Oncol. 10,311–316 (1999).
   PubMed Web of Science ®Google Scholar
• Tanko LB, McClung MR, Schimmer RC et al. The efficacy of 48-week oral ibandronate treatment in postmenopausal osteoporosis when taken 30 versus 60 min before breakfast. Bone 32,421–426 (2003).
   PubMed Web of Science ®Google Scholar
• Ralston SH, Theibaud D, Herrmann Z et al. Dose—response study of ibandronate in the treatment of cancer-associated hypercalcemia. Br.Cancer 75,295–300 (1997).
   Google Scholar
• Pecherstorfer M, Herrmann Z, Body JJ et al. Randomized Phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy. J Oncol. 14,268–276 (1996).
   Google Scholar
• Pecherstorfer M, Steunhauer EU, Rizzoli R et al. Efficacy and safety of ibandronate in the treatment of hypercalcemia of malignancy: a randomized multicentric comparison to pamidronate. Sapp. Care Cancer 11 (8), 539–547 (2003).
   PubMedGoogle Scholar
• Cruz JC, Alsina M, Craig F et al. Ibandronate decreases bone disease development and osteoclast stimulatory activity in an in vivo model of human myeloma. Exp. Hernatol. 29, 441–447 (2001).
   PubMedGoogle Scholar
• Croucher PI, Shipman CM, can Camp B et al. Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease. Cancer 97\(Suppl. 3), 818–824 (2003).
   Google Scholar
• Menssen HD, Sakalova A, Fontana A et al. Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma. Clin. Oncol. 20,2353–2359 (2002).
   Web of Science ®Google Scholar
• Terpos E, Viniou N, de la Fuente J et al. Pamidronate is superior in decreasing bone resorption, interleukin-6 and 3-2-microglobulin in multiple myeloma. Eur .j Haernatol. 70,34-42 (2003).
   Google Scholar
• Rosen LS, Gordon D, Kaminski M et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma. Cancer 98, 1735–1744 (2003).
   PubMed Web of Science ®Google Scholar
• Diel U, Body JJ, Lichinitser MR et al. Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bonde disease due to breast cancer. Eur. Cancer 40,1704–1712 (2004).
   PubMed Web of Science ®Google Scholar
• Body JJ, Diel U, Lichinitser MR et al. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann. Oncol. 14,1399–1405 (2003).
   PubMed Web of Science ®Google Scholar
• •First study to demonstrate a significant reduction of skeletal-related events in metastatic breast cancer.
   Google Scholar
• Tripathy D, Lichinitser M, Lazarev A et al. Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomized, double-blind, placebo-controlled trial. Ann. Oncol. 15,743–750 (2004).
   PubMed Web of Science ®Google Scholar
• •First study to demonstrate the equal efficacy of oral ibandronate in metastatic bone disease.
   Google Scholar
• Body JJ, Diel U, Lichinitzer M et al. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled Phase III studies. Ann. Oncol. 90,1133–1137 (2004).
   Google Scholar
• Keller ET. The role of osteoclastic activity in prostate cancer skeletal metastases. Drugs Today38, 91–102 (2002).
   PubMedGoogle Scholar
• Heidenreich A, Elert A, Hofmann R. Ibandronate in the treatment of prostate cancer associated with painful osseous metastases. Prost. Cancer Prost. Dis. 5, 231–235 (2002).
   PubMed Web of Science ®Google Scholar
• Heidenreich A, Ohlmann CH, Hofmann R. High dose ibandronate in the management of hormone refractory prostate cancer with painful osseous metastases. Eur. J Cancer Suppl. 1(5), S270 (2003).
   Google Scholar
• Small EJ, Smith MR, Seaman JJ et al. Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. JOncol. 21, 4277–4284 (2003).
   Google Scholar
• Saad F, Gleason DM, Murray R et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone refractory metastatic prostatic carcinoma. Nat] Cancer Inst. 94,1458–1468 (2002).
   PubMed Web of Science ®Google Scholar
• •First study to demonstrate a clinical benefit of aminobisphosphonates in metastatic prostate cancer.
   Google Scholar
• Fulfaro F, Arcara C, Badalamenti G et al. The use of zoledronic acid in the treatment of painful osseous metastases from prostate cancer. Proc. Am. Soc. Cilia. Oncol. 22,428 (2003) (Abstract 1721).
   Google Scholar
• Consensus Guidelines. The use of iv. bisphosphonates in the management of bone complications for patients with advanced prostate cancer. Am. J Urol Rev 2\(Suppl. 2), 5–40 (2004).
   Google Scholar
• Heidenreich A. Bisphosphonates in the management of metastatic prostate cancer. Oncology 65 (Suppl. 1), 5–11 (2003).
   Google Scholar
• Lamy O, Sandini L, Pache I et al. Intravenous ibandronate in men with osteoporosis: an open prospective study over 2 years. J Endocrinol. Invest. 26, 728–732 (2003).
   Google Scholar
• Ringe JD, Dorst A, Faber H et al. Three-monthly ibandronate bolus injection offers favourable tolerability and sustained efficacy advantage over two years in established corticosteroid-induced osteoporosis. Rheurnatology 42,743–749 (2003).
   PubMedGoogle Scholar
• Ringe JD, Dorst A, Faber H et al. Intermittent intravenous ibandronate injections reduce vertrebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study. Osteoporosis Int. 14,801–807 (2003).
   PubMed Web of Science ®Google Scholar
• Tanko LB, Mouritzen U, Lehmann HJ et al. Oral ibandronate: changes in markers of bone turnover during adequately dosed continuous and weekly therapy and during different suboptimally dosed treatment regimens. Bone 32, 687–693 (2003).
   PubMed Web of Science ®Google Scholar
• Riis BJ, Ise J, von Stein T et al. Ibandronate: a comparison of oral daily dosing versus intermittent dosing in postmenopausal osteoporosis. J Bone Miner. Res. 16,1871-1878 (2001).
   Google Scholar
• Delmas PD, Recker RR, Chesnut CH III et al. Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporosis Int. 17,1602–1609 (2004).
   Google Scholar
• Chesnut CH III, Skag A, Christiansen C et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner. Res. 19, 1241–1249 (2004).
   PubMed Web of Science ®Google Scholar
• McClung MR, Wasnich RD, Recker R et al. Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis. J Bone Miner. Res. 19,11–18 (2004).
   PubMed Web of Science ®Google Scholar
• Stakkestad JA, Benevolenskaya LI, Stepan JJ et al. Intravenous ibandronate injections given every three months are a new treatment option to prevent bone loss in postmenopausal women. Ann. Rheum. Dis. 62,969–975 (2003).
   PubMed Web of Science ®Google Scholar
• Delmas PD, ZhengQing L, Cooper C. Relationship between changes in bone mineral density and fracture risk reduction with antiresorptive drugs: some issues with meta- analyses. J Bone Miner. Res. 19, 330–337 (2004).
   Google Scholar
• Daniell HW. Osteoporosis due to androgen deprivation therapy in men with prostate cancer. Urology 58(2 Suppl. 1), 101–107 (2001).
   Google Scholar
• Diamond T, Campbell J, Bryant C et al. The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy. Cancer 83, 1561–1566 (1998).
   PubMed Web of Science ®Google Scholar
• Smith MR, McGovern FJ, Zietman AL et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl. J Med. 345, 948–955 (2001).
   PubMed Web of Science ®Google Scholar
• Orwoll E, Ettinger M, Weiss S et al. Alendronate for the treatment of osteoporosis in men. N Engl. J Med. 343, 604–610 (2000).
   PubMed Web of Science ®Google Scholar
• Tripathy D, Body JJ, Diel U et al. Intravenous and oral ibandronate alleviate pain in patients with skeletal metastases from breast cancer. San Antonio Breast Cancer Symp. (2003) (Abstract 548).
   Google Scholar
• Mancini I, Dumon J-C, Toth C, Body J-J. Short-term treatment with the bisphosphonate ibandronate for opioid-resistant metastatic bone pain. Bone 30 (Suppl. 3), 51(2002) (Abstract B56).
   Google Scholar
• Heidenreich A, Ohlmann CH, Hofmann R. Ibandronate in the management of painful osseous metastases due to hormone refractory prostate cancer. Supportive Care in Cancer 11,396 (2003) (Abstract 38).
   Google Scholar
• Hiraga T, Williams PJ, Mundy GR et al. The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases. Cancer Res. 61,4418–4424(2000.
   Google Scholar
• Neudert M, Fischer C, Krempien B et al. Site-specific human breast cancer (MDA-MB- 231) metastases in nude rats: model characterisation and in vivo effects of ibandronate on tumour growth. Int. J Cancer 107,468–477 (2003).
   Google Scholar
• Michigami T, Hiraga T, Williams PJ et al. The effect of bisphosphonate ibandronate on breast cancer metastasis in visceral organs. Breast Cancer Res. Treat. 75,249–258 (2002).
   PubMed Web of Science ®Google Scholar
• Magnetto S, Boissier S, Delmas PD et al. Additive antitumor effects of taxoids in combination with the bisphosphonate ibandronate against invasion and adhesion of human breast carcinoma cells to bone. Int.j Cancer 83,263–269 (1999).
   PubMed Web of Science ®Google Scholar
• Yi B, Williams PJ, Niewolna M et al. Reduction of osteoblastic bone metastases by the bisphosphonate ibandronate. J Bone Miner. Res.14\(Suppl. 1), 5A055 (1999).
   Google Scholar
• Zojer N, Keck AV, Pecherstorfer M. Comparative tolerability of drug therapies for hypercalcaemia of maligancy. Drug Sal. 21,389–406 (1999).
   Google Scholar
• Adami S, Felsenberg D, Christainsen C et al. Efficacy and safety of ibandronate given by intravenous injection once every 3 months. Bone 34,881–889 (2004).
   PubMedGoogle Scholar
• Syrigos KN, Michalaki V, Mitromaras A et al. Safety and efficacy of the new bisphosphonate ibandronate in the management of bone metastases following rapid infusion. In Vivo 16,361–363 (2002).
   PubMedGoogle Scholar
• Heidenreich A, Ohlmann CH, Hoffmann R. Ibandronate in the management of tumor-induced hypercalcemia and bone pain in patients with renal insufficiency. Eur. Cancer Suppl. 1, S271 (2003).
   Google Scholar
• Body JJ. Dosing regims and main adverse events of bisphosphonates. Sernin. Oncol. 28\(Suppl. 11), 49–53 (2001).
   Google Scholar